Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenues		$ 4,000,000
Operating expenses:
Research, development and patents	$ 2,111,996	2,145,274
General and administrative	1,298,016	2,056,255
Total operating expenses	3,410,012	4,201,529
Operating loss	(3,410,012)	(201,529)
Interest income	37,339	36,668
Other expense	(13,744)	(22,938)
Net loss applicable to common stockholders	$ (3,386,417)	$ (187,799)
Basic and diluted net loss per common share	$ (0.07)	$ 0.00
Shares used to compute basic and diluted net loss per common share	49,043,246	47,535,307
Net loss applicable to common stockholders	$ (3,386,417)	$ (187,799)
Other comprehensive loss, net of tax:
Foreign currency translation adjustments	(7,435)	(6,821)
Comprehensive loss	$ (3,393,852)	$ (194,620)